Insulin Pump Maker’s 900% Stock Surge Has More Room to Run

Tandem Diabetes Care Inc. bulls still see upside for the insulin pump maker, even after shares increased ten-fold so far this year. Sell-side analysts rushed to boost their price targets for one of the Russell 2000 Index’s best performers in the wake of last week’s Food and Drug Administration approval of a technology for the company’s insulin pump. Piper Jaffray analyst JP McKim called the approval a “game changer” that will help attract patients and give them reason to upgrade to newer pumps. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.